This company has been acquired
Covetrus Future Growth
Future criteria checks 0/6
Key information
n/a
Earnings growth rate
54.7%
EPS growth rate
Healthcare earnings growth | 18.9% |
Revenue growth rate | 5.6% |
Future return on equity | 10.6% |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line
Aug 04Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders
Jun 02Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price
May 02Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?
Jan 07We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Oct 21An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued
Sep 16Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)
May 31Covetrus, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Is Covetrus (NASDAQ:CVET) Using Too Much Debt?
May 05Covetrus, Inc.: Well Positioned To Enjoy Market Crosscurrents
Apr 30Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?
Feb 26We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Jan 22Covetrus reports Q4 net sales of prescription management business
Jan 13Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain
Dec 18Covetrus, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 12Covetrus Q3 2020 Earnings Preview
Nov 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 5,341 | N/A | 125 | N/A | 2 |
12/31/2023 | 5,065 | N/A | 92 | N/A | 4 |
12/31/2022 | 4,789 | N/A | 112 | N/A | 4 |
6/30/2022 | 4,649 | -13 | 2 | 60 | N/A |
3/31/2022 | 4,621 | -40 | 70 | 126 | N/A |
12/31/2021 | 4,575 | -54 | 42 | 102 | N/A |
9/30/2021 | 4,575 | -56 | 44 | 104 | N/A |
6/30/2021 | 4,539 | -90 | -60 | 2 | N/A |
3/31/2021 | 4,376 | -13 | 10 | 72 | N/A |
12/31/2020 | 4,339 | -26 | -5 | 53 | N/A |
9/30/2020 | 4,225 | -19 | 31 | 80 | N/A |
6/30/2020 | 4,117 | -940 | 112 | 154 | N/A |
3/31/2020 | 4,100 | -996 | 18 | 58 | N/A |
12/31/2019 | 3,976 | -980 | 64 | 103 | N/A |
9/30/2019 | 3,871 | -948 | 93 | 130 | N/A |
6/30/2019 | 3,776 | 27 | 83 | 113 | N/A |
3/31/2019 | 3,772 | 65 | 131 | 157 | N/A |
12/29/2018 | 3,778 | 101 | 136 | 158 | N/A |
9/30/2018 | 3,791 | 69 | 74 | 94 | N/A |
6/30/2018 | 3,776 | 74 | 103 | 127 | N/A |
3/31/2018 | 3,649 | 67 | 42 | 64 | N/A |
12/30/2017 | 3,580 | 64 | 87 | 108 | N/A |
12/31/2016 | 3,353 | 70 | 92 | 105 | N/A |
12/26/2015 | 2,978 | 60 | N/A | 96 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CVET's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if CVET's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CVET's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CVET's revenue (5.6% per year) is forecast to grow slower than the US market (7.3% per year).
High Growth Revenue: CVET's revenue (5.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CVET's Return on Equity is forecast to be low in 3 years time (10.6%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/10/16 09:03 |
End of Day Share Price | 2022/10/12 00:00 |
Earnings | 2022/06/30 |
Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Covetrus, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Argus Research Company |
Robert Eich | Cleveland Research Company |
Erin Wilson Wright | Credit Suisse |